Skip to main content

Table 2 Baseline characteristics of patients at enrolment in the two groups

From: Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial

  Artesunate Mefloquine (n = 157) Artemether Lumefantrine (n = 153) p value
Age (mean ± SD, years) 25 ± 11 23.2 ± 10,5 0.15
Weight (mean ± SD, Kg) 62.1 ± 11.8 58.2 ± 11.5 0.08
Sex ratio (male/female) 1.2 0.6 0.03
Temperature (mean ± SD) 37.8 ± 1.2 37.7 ± 1.1 0.41
Median Parasitemia (trophozoites/μL) 17411 17688 0.88
Mean haemoglobin (g/dl) 12.2 ± 1.7 11.7 ± 1.7 0.99
Anaemia (Hb < 11 g/dl,%) 36.3 40.5 0.44
ASAT (UI/L, mean ± SD) 31.2 ± 18.7 33.1 ± 16.8 0.38
Patients with normal level of ASAT (ASAT < 40 UI/L) (%) 128 (81.5%) 123 (80.4%) 0.79
ALAT (UI/L, mean ± SD) 28.2 ± 20.3 26.3 ± 24.1 0.47
Patients with normal level of ALAT (ALAT < 40 UI/L) (%) 119 (82.1%) 138 (90.2%) 0.04
Creatinine (mean ± SD) 7.6 ± 5.4 8.2 ± 3.5 0.24
Patients with normal level of creatinine (<13 mg/L) (%) 148 (94.3%) 143 (93.5%) 0.76
Median Bilirubunemia (mg/L) 1.91 1.71 0.51
Patients with normal level of Biliribunemia (<10 mg/L) (%) 48 (30.6%) 55 (35.9%) 0.31